Cracking the therapeutic nut in mild cognitive impairment: better nuts and better nutcrackers.
Knopman
David S
DS
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000517:prevention & control*; D015415:Biomarkers / Q000032:analysis; D002800:Cholinesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003072:Cognition Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D018450:Disease Progression; D000077265:Donepezil; D006801:Humans; D007189:Indans / Q000494:pharmacology* / Q000627:therapeutic use; D009483:Neuropsychological Tests / Q000592:standards; D017063:Outcome Assessment, Health Care / Q000379:methods* / Q000592:standards; D010880:Piperidines / Q000494:pharmacology* / Q000627:therapeutic use; D012107:Research Design / Q000592:standards; D017211:Treatment Failure
D015415:Biomarkers; D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D000077265:Donepezil